Professional
Added to YB: 2024-08-21
Pitch date: 2024-06-30
GKOS [bullish]
Glaukos Corporation
-7.92%
current return
Author Info
No bio for this author
Company Info
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Market Cap
$5.2B
Pitch Price
$118.24
Price Target
N/A
Dividend
N/A
EV/EBITDA
-102.02
P/E
-58.28
EV/Sales
10.65
Sector
Health Care Equipment and Supplies
Category
growth
Baron Health Care Fund New Position: Glaukos Corporation
GKOS: Launching iDose, minimally invasive glaucoma treatment. 3-yr+ drug delivery device improves compliance (90% non-compliance w/ eye drops) & reduces side effects. 3M US glaucoma patients, 6M potential. $1B product potential. Bullish on large market ripe for standalone interventions.
Read full article (1 min)